215 related articles for article (PubMed ID: 32448667)
1. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E
Transplant Proc; 2020 Oct; 52(8):2520-2523. PubMed ID: 32448667
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
5. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
7. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
8. Kidney Transplantation in a Patient With Tuberous Sclerosis Complex: A Case Report.
Kluz A; Gozdowska J; Domagała P; Durlik M
Transplant Proc; 2022 May; 54(4):1148-1151. PubMed ID: 35430095
[TBL] [Abstract][Full Text] [Related]
9. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
[TBL] [Abstract][Full Text] [Related]
11. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
Kronick J; Gabril MY; House AA
Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
[TBL] [Abstract][Full Text] [Related]
12. Renal transplant in a tuberous sclerosis patient with bilateral giant renal angiomyolipomas and concurrent renal carcinoma.
Hussain M; Mubarak M; Sultan G; Ahmed E; Yunus M; Salehi MA; Asif M; Anwer Naqvi SA; Rizvi SA
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):318-21. PubMed ID: 23538357
[TBL] [Abstract][Full Text] [Related]
13. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
14. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
15. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma.
Patel U; Simpson E; Kingswood JC; Saggar-Malik AK
Clin Radiol; 2005 Jun; 60(6):665-73; discussion 663-4. PubMed ID: 16038693
[TBL] [Abstract][Full Text] [Related]
16. From tuberous sclerosis complex to end stage renal disease: who are these patients?
Vabret E; Couchoud C; Lassalle M; Vigneau C
J Nephrol; 2021 Apr; 34(2):607-615. PubMed ID: 32130718
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex: Hamartin and tuberin expression in renal cysts and its discordant expression in renal neoplasms.
Bonsib SM; Boils C; Gokden N; Grignon D; Gu X; Higgins JP; Leroy X; McKenney JK; Nasr SH; Phillips C; Sangoi AR; Wilson J; Zhang PL
Pathol Res Pract; 2016 Nov; 212(11):972-979. PubMed ID: 27640314
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis, associated with renal cell carcinoma and angiomyolipoma, in a patient who developed endstage renal failure after nephrectomy.
Kida Y; Yamaguchi K; Suzuki H; Kanda E; Ando M; Ohashi K; Funata N; Saito H
Clin Exp Nephrol; 2005 Jun; 9(2):179-82. PubMed ID: 15980956
[TBL] [Abstract][Full Text] [Related]
19. Developing multiple lung nodules in a renal transplant recipient with tuberous sclerosis who had undergone bilateral nephrectomy due to renal cell carcinomas.
Saito M; Yuasa T; Satoh S; Nanjo H; Tsuchiya N; Habuchi T
Int J Urol; 2008 Mar; 15(3):257-8. PubMed ID: 18304223
[TBL] [Abstract][Full Text] [Related]
20. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
